AnodyneWiki

Lisdexamphetamine

Vyvanse
Lisdexamphetamine
Salts
[]
Lisdexamphetamine didimesylate
Lisdexamphetamine didimesylate
Lisdexamphetamine sulfate
Lisdexamphetamine sulfate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass263.38 g/mol [1]
AppearanceGolden-colored solid from methanol [1]
Melting point191-193 [1]
Solubility792 mg/mL [1]
Predicted LogP1.2 [1]
Structural Identifiers
[]
Molecular formulaC15H25N3O
IUPAC name(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
SMILESC[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
InChIInChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
InChIKeyVOBHXZCDAVEXEY-JSGCOSHPSA-N
CAS number608137-32-2
UNIIH645GUL8KJ
PubChem CID11597698
Pharmacokinetics[]
OnsetOral: <2 hours[3][4]
Elimination half-lifeLisdexamfetamine: <1 hour, Dextroamphetamine: 10–12 h
Duration of action10–14 hours[5]
MetabolismHydrolysis by enzymes in red blood cells initially, subsequent metabolism follows
ExcretionKidney: ~2% as Lisdexamfetamine and ~42% as Dextroamphetamine
Routes of administrationOral
Dependence liabilityPhysical: None, Psychological: Moderate[6][7]
Addiction liabilityModerate

Lisdexamphetamine (also known as L-lysine-d-amphetamine, lisdexanfetamina, L-lysine-dextroamphetamine, lisdexamfetaminum, (2S)-2,6-Diamino-N-((1S)-1-methyl-2-phenylethyl)hexanamide, (2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide, (2S)-2,6-diamino-N-((2S)-1-phenylpropan-2-yl)hexanimidic acid, (2S)-2,6-diamino-N-((2S)-1-phenylpropan-2-yl)hexanamide, (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanimidic acid or N06ba12) is a codrug, prodrug and stimulant substance of the amphetamine class.

Chemistry

Salts []

Lisdexamphetamine is typically found in the form of its didimesylate and sulfate salts.

 []

Lisdexamphetamine is a single defined stereoisomer.

Lisdexamphetamine matches Lipinski's rule of five.

There are currently 3 reagent-interactions on

ReagentColor changeDescription
Marquisorange
Meckeno color change
Mandelinno color change

Pharmacology

Mechanism of action []

Lisdexamfetamine is a prodrug of dextroamphetamine, which is a noncatecholamine sympathomimetic amine with CNS stimulant activity. Dextroamphetamine is a known inhibitor of the dopamine transporter (DAT), noradrenaline transporter (NET) and vesicular monoamine transporter 2 (VMAT2), with a weaker affinity for the serotonin transporter (SERT). It is also a weak monoamine oxidase (MAO) inhibitor. Dextroamphetamine ultimately blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases catecholamine availability in the extracellular space. The exact mode of therapeutic action of lisdexamfetamine in ADHD and BED has not been fully elucidated; however, the clinical effects of lisdexamfetamine are believed to be linked to the pharmacological actions of dextroamphetamine. [1]

Metabolism

Lisdexamphetamine acts as a for:

Metabolic pathways []
Lisdexamphetamine
→ Lysine

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target37
shared target2

Medical side effects []

80 side effects listed on drug labels in (lisdexamfetamine).

  • Decreased appetite
  • Anorexia
  • Malnutrition
  • Insomnia
  • Mental disorder
  • Gastrointestinal disorder
  • Digestion impaired
  • Abdominal pain upper
  • Irritability
  • Vomiting
  • Weight decreased
  • Nausea
  • Anxiety
  • Dry mouth
  • Nervousness
  • Feeling jittery
  • Diarrhoea
  • Hyperhidrosis
  • Agitation
  • Skin disorder
  • Affect lability
  • Blood pressure increased
  • Dizziness
  • Dyspnoea
  • Body temperature increased
  • Mediastinal disorder
  • Nervous system disorder
  • Dermatitis
  • Rash
  • Tachycardia
  • Tremor
  • Somnolence
  • Aggression
  • Anaphylactic shock
  • Angioedema
  • Bruxism
  • Constipation
  • Sudden death
  • Depression
  • Diplopia
  • Dyskinesia
  • Toxic epidermal necrolysis
  • Eye disorder
  • Asthenia
  • Fatigue
  • Hallucination
  • Headache
  • Cardiac disorder
  • Hepatitis
  • Hypersensitivity
  • Immune system disorder
  • Mydriasis
  • Myocardial infarction
  • Acute coronary syndrome
  • Palpitations
  • Convulsion
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Cerebrovascular accident
  • Tourette's disorder
  • Urticaria
  • Dyspepsia
  • Dysphoria
  • Euphoric mood
  • Erectile dysfunction
  • Hepatobiliary disease
  • Psychotic disorder
  • Mania
  • Vision blurred
  • Cardiomyopathy
  • Dermatillomania
  • Logorrhoea
  • Libido decreased
  • Disturbance in sexual arousal
  • Hypertension
  • Weight increased
  • Ventricular hypertrophy
  • Initial insomnia
  • Middle insomnia
  • Visual impairment

Indications

  • Attention deficit disorder
  • Attention deficit/hyperactivity disorder
  • Forgetfulness
  • Hyperkinesia
  • Mental disorder
  • Psychotic disorder

Subjective effects []

0xea / Lisdexamphetamine []
Routes:
  • Oral (30 - 150mg)
    Onset: 1.5 - 2 h
    Duration: 7 - 13 h
  • Intravenous (50 - 150mg)
    Onset: 1 h
    Duration: ?
Classes:Forms:
  • Dimesylate
Source:
  • Elvanse Lisdexamfetamine Dimesylate
Indication:
  • executive dysfunction
Effects:Tolerance:
  • builds steadily over the span of weeks to months
a1ko / Lisdexamphetamine []
Routes:
  • Insufflated (30 - 60mg)
  • Oral (30 - 120mg)
alina / Lisdexamphetamine []
Routes:
  • Oral (10 - 60mg)
bonzi / Lisdexamphetamine []
Routes:
  • Oral (20 - 70mg)
emily / Lisdexamphetamine []
Routes:
  • Oral (10 - 80mg)
magnus / Lisdexamphetamine []
Routes:
  • Oral (70mg)
Forms:
  • Dimesylate
Effects:Notes:
Mere / Lisdexamphetamine []
ninerik / Lisdexamphetamine []
Routes:
  • Oral (20mg)
Classes:Forms:
  • Dimesylate
Source:
  • Friend
Notes:
  • Ik ben de situatie aan het monitoren
Pilz / Lisdexamphetamine []
Routes:
  • Oral (5 - 60mg)
Forms:
  • Dimesylate
Source:
  • Elvanse capusles
  • Lisdexamphetamin-ratiopharm capsules
Indication:Effects:Notes:
  • Best ADHD-Medication ive tried

Experience reports

Reddit

There are currently 22 trip reports involving lisdexamphetamine on : []

 []

  • Australia: Lisdexamphetamine is a Schedule 8.[8]
  • Brazil: Lisdexamphetamine is a Class A3.[9]
  • Germany: Lisdexamphetamine is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
  • New Zealand: Lisdexamphetamine is a Class B.
  • United Kingdom: Lisdexamphetamine is a Class B under the "Misuse of Drugs Act 1971".
  • United States: Lisdexamphetamine is a Schedule II under the "Controlled Substances Act".[10]
  • European Union: Lisdexamphetamine is Prescription only.[11]
  • Other: Lisdexamphetamine is a SE: Förteckning II MX: Controlled / Rx-only.[12][13][14][15]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 11597698, Lisdexamphetamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/11597698
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lisdexamphetamine. UNII: H645GUL8KJ. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/H645GUL8KJ
  3. Millichap JG. Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD. Springer. 2010.
  4. Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgraduate Medicine. September 2008; 120(3):69–88. PMID 18824827. https://doi.org/10.3810/pgm.2008.09.1909
  5. Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. March 2017.
  6. Adderall vs Vyvanse - What's the difference between them?. Drugs.com. https://www.drugs.com/medical-answers/adderall-vs-vyvanse-3013810/
  7. Goodman DW. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P & T. May 2010; 35(5):273–287. PMID 20514273.
  8. Australian Product Information Vyanse® (Lisdexamfetamine dimesilate). Department of Health and Aged Care. https://www.tga.gov.au/sites/default/files/auspar-lisdexamfetamine-dimesilate-180515-pi.pdf
  9. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  10. Vyvanse- lisdexamfetamine dimesylate capsule; Vyvanse- lisdexamfetamine dimesylate tablet, chewable. DailyMed. 10 March 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad
  11. List of nationally authorised medicinal products : Active substance(s): lisdexamfetamine : Procedure No. PSUSA/00010289/202002. Ema.europa.eu. https://www.ema.europa.eu/documents/psusa/lisdexamfetamine-list-nationally-authorised-medicinal-products-psusa/00010289/202002_en.pdf
  12. Lisdexamfetamindimesilat. https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/substans/v2va9rlain4srv01/lisdexamfetamindimesilat
  13. Elvanse (Kapsel, hård 30 mg) • Fass vy &#124; FASS Vård. https://fass.se/health/product/20111213000092#:~:text=Om%20l%C3%A4kemedlet-,Narkotikaklass%20II,-S%C3%A4rskilt%20l%C3%A4kemedel
  14. Anexo "Fracciones Arancelarias". Comisión Nacional de Mejora Regulatoria. https://www.cofemersimir.gob.mx/expediente/25222/mir/50628/anexo/5992654
  15. Ley General de Salud. Cámara de Diputados del H. Congreso de la Unión. 15 January 2026. https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 09:59:30
drugsprook2026-11-20 09:59:26
erowidmissing (no Erowid substance of that name)2026-11-20 09:59:26
gsrsok2026-11-20 09:59:26
hmdbmissing (hmdb.ca refused automated access to HMDB0015385)2026-11-20 09:59:26
keggok2026-11-20 09:59:28
pubchemok2026-11-20 09:59:26
redditok2026-11-20 09:59:26
siderok2026-11-20 09:59:26
structureok2026-11-20 09:59:26
wikipediaok2026-11-20 09:59:26